Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric HIV Clear all
Completed Not applicable Interventional

Piloting At-birth Point of Care HIV Testing Strategies in Kenya

NCT03435887
View directory record Official record
Conditions
HIV Infections
Interventions
Alere q HIV-1/2 Detect for point of care infant testing, GeneXpert HIV-1 Qual for point of care infant testing, HIV DNA PCR testing (Standard of Care)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

Capravirine to Treat Children With HIV Infection

NCT00006519
View directory record Official record
Conditions
HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2006 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional

A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine

NCT00002263
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
6 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 8:10 AM EDT
Not listed Phase 2 Interventional

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

NCT02291809
View directory record Official record
Conditions
HIV/AIDS
Interventions
REMUNE
Biological
Lead sponsor
Immune Response BioPharma, Inc.
Industry
Eligibility
3 Months to 16 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Lopinavir/Ritonavir (Kaletra) PK in Children

NCT00810108
View directory record Official record
Conditions
HIV/AIDS Treatment, HIV Infections
Interventions
lopinavir/ritonavir (Kaletra®) tablets
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 17 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
San Diego, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2012 · Synced Sep 10, 2026, 8:10 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process

NCT02785302
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 10, 2026, 8:10 AM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
View directory record Official record
Conditions
HIV Infections
Interventions
TRIUMEQ, DOVATO
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

NCT00000901
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional

A Study of 1592U89 in HIV-Infected Children

NCT00002197
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
6 Months to 13 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Taste Properties of Atazanavir and Cobicistat

NCT02307656
View directory record Official record
Conditions
HIV in Adults
Interventions
Atazanavir, Cobicistat, Active Pharmaceutical Ingredient
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 10, 2026, 8:10 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 8:10 AM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed No phase listed Observational

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

NCT00153621
View directory record Official record
Conditions
Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2008 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

NCT00002391
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

NCT01691794
View directory record Official record
Conditions
HIV, Pediatric
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2011 · Synced Sep 10, 2026, 8:10 AM EDT